Back to top

Tale of the Tape

Zacks Equity Research

Can The Uptrend Continue for Stemline Therapeutics (STML)?
October 14, 2016


Trades from $3

Investors certainly have to be happy with Stemline Therapeutics, Inc. (STML - Snapshot Report) and its short term performance. After all, the stock has jumped by 40.3% in the past 4 weeks, and it is also above its 20 Day Simple Moving Average as well. This is certainly a good trend, but investors are probably asking themselves, can this positive trend continue for STML?

While we can never know for sure, it is pretty encouraging that estimates for STML have moved higher in the past few weeks, meaning that analyst sentiment is moving in the right way. Plus, the stock actually has a Zacks Rank #2 (Buy), so the recent move higher for this spotlighted company may definitely continue over the next few weeks. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Confidential from Zacks

Beyond this Tale of the Tape, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>

In-Depth Zacks Research for the Tickers Above